9 Meters Biopharma Inc. (NMTRQ)

OTCMKTS: NMTRQ · Delayed Price · USD
0.00
0.00 (0.00%)
Mar 27, 2024, 10:59 AM EDT - Market open

Company Description

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America.

Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome.

The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease.

Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome.

The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS.

9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

9 Meters Biopharma Inc.
9 Meters Biopharma logo
Country United States
Founded 2012
Industry Biotechnology
Sector Healthcare
Employees 10
CEO Sandeep Laumas

Contact Details

Address:
4509 Creedmoor Road, Suite 600
Raleigh, North Carolina 27612
United States
Phone 919-275-1933

Stock Details

Ticker Symbol NMTRQ
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001551986
Employer ID 27-3948465
SIC Code 2834

Key Executives

Name Position
Dr. Peter H. R. Green M.D. Clinical and Scientific Advisor and Consultant
Joseph A. Murray M.D. Clinical and Scientific Advisor and Consultant
Dr. Ciaran P. Kelly M.D. Clinical and Scientific Advisor and Consultant
Dr. Elena Verdu M.D., Ph.D. Clinical and Scientific Advisor and Consultant
Markku Mäki M.D., Ph.D. Clinical and Scientific Advisor and Consultant
Dr. William J. Sandborn M.D., Ph.D. Clinical and Scientific Advisor and Consultant
Dr. Roger Liddle M.D. Clinical and Scientific Advisor and Consultant
Dr. Anthony J. Dimarino Jr. Clinical and Scientific Advisor and Consultant
Dr. Brian Gordon Feagan FRCPC, M.D., M.P.H. Clinical and Scientific Advisor and Consultant
Dr. Aida Habtezion M.D., M.Sc. Clinical and Scientific Advisor and Consultant

Latest SEC Filings

Date Type Title
Feb 7, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Sep 8, 2023 25-NSE Filing
Jul 21, 2023 144 Filing
Jul 19, 2023 144 Filing
Jul 18, 2023 8-K Current Report
Jun 16, 2023 8-K Current Report
May 30, 2023 8-K Current Report
May 22, 2023 8-K Current Report
May 19, 2023 PRE 14A Other preliminary proxy statements
May 19, 2023 8-K Current Report